A citation-based method for searching scientific literature

Xiaocui Qin, Xia Zhang, Pinyu Li, Min Wang, Li Yan, Zeqing Bao, Qili Liu. Front Neurol 2021
Times Cited: 8







List of co-cited articles
67 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges.
Francesco Agostini, Anna Masato, Luigi Bubacco, Marco Bisaglia. Int J Mol Sci 2021
10
50

Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus.
Qian Shi, Shuqian Liu, Vivian A Fonseca, Tina K Thethi, Lizheng Shi. BMJ Open 2019
50
37

Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease.
Nikita Katila, Sunil Bhurtel, Sina Shadfar, Sunil Srivastav, Sabita Neupane, Uttam Ojha, Gil-Saeng Jeong, Dong-Young Choi. Neuropharmacology 2017
87
37

Metformin Scavenges Methylglyoxal To Form a Novel Imidazolinone Metabolite in Humans.
Owen R Kinsky, Tiffanie L Hargraves, Tarun Anumol, Neil E Jacobsen, Jixun Dai, Shane A Snyder, Terrence J Monks, Serrine S Lau. Chem Res Toxicol 2016
53
37

Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction.
Ming-Chang Chiang, Yi-Chuan Cheng, Shiang-Jiuun Chen, Chia-Hui Yen, Rong-Nan Huang. Exp Cell Res 2016
58
37

Protective effect of metformin against rotenone-induced parkinsonism in mice.
Dong-Xin Wang, An-Di Chen, Qing-Jun Wang, Yue-Yang Xin, Jie Yin, Yu-Hong Jing. Toxicol Mech Methods 2020
10
37

Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
Yi-Chun Kuan, Kuang-Wei Huang, Cheng-Li Lin, Chaur-Jong Hu, Chia-Hung Kao. Prog Neuropsychopharmacol Biol Psychiatry 2017
81
37

Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.
José A Luchsinger, Thania Perez, Helena Chang, Pankaj Mehta, Jason Steffener, Gnanavalli Pradabhan, Masanori Ichise, Jennifer Manly, Davangere P Devanand, Emilia Bagiella. J Alzheimers Dis 2016
131
37

Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress.
Tsu-Kung Lin, Kai-Jung Lin, Hung-Yu Lin, Kai-Lieh Lin, Min-Yu Lan, Pei-Wen Wang, Tzu-Jou Wang, Feng-Sheng Wang, Po-Chin Tsai, Chia-Wei Liou,[...]. Front Mol Neurosci 2021
13
37


Activation of AMPK/aPKCζ/CREB pathway by metformin is associated with upregulation of GDNF and dopamine.
Nikita Katila, Sunil Bhurtel, Pil-Hoon Park, Jin Tae Hong, Dong-Young Choi. Biochem Pharmacol 2020
11
25

The Synucleinopathies: Twenty Years On.
Michel Goedert, Ross Jakes, Maria Grazia Spillantini. J Parkinsons Dis 2017
239
25

Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Mark L Wahlqvist, Meei-Shyuan Lee, Chih-Cheng Hsu, Shao-Yuan Chuang, Jiunn-Tay Lee, Hsin-Ni Tsai. Parkinsonism Relat Disord 2012
151
25

Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system.
Afrah A K Ismaiel, Ana M Espinosa-Oliva, Martiniano Santiago, Albert García-Quintanilla, María J Oliva-Martín, Antonio J Herrera, José L Venero, Rocío M de Pablos. Toxicol Appl Pharmacol 2016
42
25

Increased risk of cognitive impairment in patients with diabetes is associated with metformin.
Eileen M Moore, Alastair G Mander, David Ames, Mark A Kotowicz, Ross P Carne, Henry Brodaty, Michael Woodward, Karyn Boundy, Kathryn A Ellis, Ashley I Bush,[...]. Diabetes Care 2013
225
25

Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation.
B I Pérez-Revuelta, M M Hettich, A Ciociaro, C Rotermund, P J Kahle, S Krauss, D A Di Monte. Cell Death Dis 2014
87
25

Cellular and Molecular Mechanisms of Metformin Action.
Traci E LaMoia, Gerald I Shulman. Endocr Rev 2021
90
25

Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria.
Danielle E Mor, Salman Sohrabi, Rachel Kaletsky, William Keyes, Alp Tartici, Vrinda Kalia, Gary W Miller, Coleen T Murphy. Proc Natl Acad Sci U S A 2020
48
25

Neuroprotective effect of metformin on dopaminergic neurodegeneration and α-synuclein aggregation in C. elegans model of Parkinson's disease.
Nada Saewanee, Theethawat Praputpittaya, Nawaphat Malaiwong, Pawanrat Chalorak, Krai Meemon. Neurosci Res 2021
21
25

Disruption of mitochondrial complex I induces progressive parkinsonism.
Patricia González-Rodríguez, Enrico Zampese, Kristen A Stout, Jaime N Guzman, Ema Ilijic, Ben Yang, Tatiana Tkatch, Mihaela A Stavarache, David L Wokosin, Lin Gao,[...]. Nature 2021
77
25

Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies.
Hugo Vicente Miranda, Éva M Szego, Luís M A Oliveira, Carlo Breda, Ekrem Darendelioglu, Rita M de Oliveira, Diana G Ferreira, Marcos A Gomes, Ruth Rott, Márcia Oliveira,[...]. Brain 2017
106
25

Role of AMP-activated protein kinase in mechanism of metformin action.
G Zhou, R Myers, Y Li, Y Chen, X Shen, J Fenyk-Melody, M Wu, J Ventre, T Doebber, N Fujii,[...]. J Clin Invest 2001
25

Metformin attenuates rotenone-induced oxidative stress and mitochondrial damage via the AKT/Nrf2 pathway.
Nikita Katila, Sunil Bhurtel, Pil-Hoon Park, Dong-Young Choi. Neurochem Int 2021
10
25

Functionalized polyanhydride nanoparticles for improved treatment of mitochondrial dysfunction.
Benjamin W Schlichtmann, Balaraman Kalyanaraman, Rainie L Schlichtmann, Matthew G Panthani, Vellareddy Anantharam, Anumantha G Kanthasamy, Surya K Mallapragada, Balaji Narasimhan. J Biomed Mater Res B Appl Biomater 2022
3
66

Divergent Effects of Metformin on an Inflammatory Model of Parkinson's Disease.
Khadija Tayara, Ana M Espinosa-Oliva, Irene García-Domínguez, Afrah Abdul Ismaiel, Antonio Boza-Serrano, Tomas Deierborg, Alberto Machado, Antonio J Herrera, José L Venero, Rocío M de Pablos. Front Cell Neurosci 2018
29
25

The Role of Cholesterol in α-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease.
Patricia García-Sanz, Johannes M F G Aerts, Rosario Moratalla. Mov Disord 2021
25
25

Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.
Jayasankar Kosaraju, Vishakantha Murthy, Rizwan Basha Khatwal, Anil Dubala, Santhivardhan Chinni, Satish Kumar Muthureddy Nataraj, Duraiswamy Basavan. J Pharm Pharmacol 2013
97
25


Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
Ghada A Badawi, Mai A Abd El Fattah, Hala F Zaki, Moushira I El Sayed. Neurotox Res 2019
21
25

Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation.
Olga Moiseeva, Xavier Deschênes-Simard, Emmanuelle St-Germain, Sebastian Igelmann, Geneviève Huot, Alexandra E Cadar, Véronique Bourdeau, Michael N Pollak, Gerardo Ferbeyre. Aging Cell 2013
307
25

Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.
Ghada A Badawi, Mai A Abd El Fattah, Hala F Zaki, Moushira I El Sayed. Inflammopharmacology 2017
59
25

Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Jian-Bo Zhou, Xingyao Tang, Min Han, Jinkui Yang, Rafael Simó. Metabolism 2020
27
25

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
361
25


PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease.
Meira Maria Forcelini Machado, Taysa Bervian Bassani, Valentín Cóppola-Segovia, Eric Luiz Rossa Moura, Silvio Marques Zanata, Roberto Andreatini, Maria Aparecida Barbato Frazão Vital. Pharmacol Rep 2019
33
25

DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling.
Shuyi Chen, Mei Zhou, Jie Sun, Ai Guo, Roger Lakmal Fernando, Yanlin Chen, Peng Peng, Gang Zhao, Yanqiu Deng. Neuropharmacology 2019
33
25


Increased risk of Parkinson disease with diabetes mellitus in a population-based study.
Yu-Wan Yang, Teng-Fu Hsieh, Chia-Ing Li, Chiu-Shong Liu, Wen-Yuan Lin, Jen-Huai Chiang, Tsai-Chung Li, Cheng-Chieh Lin. Medicine (Baltimore) 2017
65
25

Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
291
25

Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice.
S P Patil, P D Jain, P J Ghumatkar, R Tambe, S Sathaye. Neuroscience 2014
162
25

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.
Tomohiko Sato, Haruo Hanyu, Kentaro Hirao, Hidekazu Kanetaka, Hirofumi Sakurai, Toshihiko Iwamoto. Neurobiol Aging 2011
279
25

PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Nicoletta Schintu, Lucia Frau, Marcello Ibba, Pierluigi Caboni, Arianna Garau, Ezio Carboni, Anna R Carta. Eur J Neurosci 2009
167
25

Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice.
Zhenri Ou, Xuejian Kong, Xiangdong Sun, Xiaosong He, Le Zhang, Zhuo Gong, Jingyi Huang, Biao Xu, Dahong Long, Jianhua Li,[...]. Brain Behav Immun 2018
173
25

Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
Ruth Brauer, Li Wei, Tiantian Ma, Dilan Athauda, Christine Girges, Nirosen Vijiaratnam, Grace Auld, Cate Whittlesea, Ian Wong, Tom Foltynie. Brain 2020
49
25

Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study.
Aaron M Koenig, Dawn Mechanic-Hamilton, Sharon X Xie, Martha F Combs, Anne R Cappola, Long Xie, John A Detre, David A Wolk, Steven E Arnold. Alzheimer Dis Assoc Disord 2017
162
25

Diabetes mellitus and the risk of dementia: The Rotterdam Study.
A Ott, R P Stolk, F van Harskamp, H A Pols, A Hofman, M M Breteler. Neurology 1999
25


Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease.
James L Searcy, Jeremiah T Phelps, Tristano Pancani, Inga Kadish, Jelena Popovic, Katie L Anderson, Tina L Beckett, Michael P Murphy, Kuey-Chu Chen, Eric M Blalock,[...]. J Alzheimers Dis 2012
108
25

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
172
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.